News | February 02, 2010

Hologic Reports Revenues of $412.4 Million

Selenia

February 2, 2010 - Hologic reported its first quarter 2010 net income was $26.1 million, or 10 cents per diluted share, calculated in accordance with U.S. generally accepted accounting principles (GAAP).

A manufacturer of women's diagnostic medical devices, currently Hologic holds a leading position in nine technology areas serving women's health, including breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing, and osteoporosis detection.

First quarter 2010 non-GAAP adjusted net income reached $74.6 million, or 29 cents per diluted share, and adjusted EBITDA (non-GAAP adjusted earnings before interest, taxes, depreciation and amortization) was $147.2 million.

The company reduced its term loan to fund on the Third Wave Technologies acquisition from an initial balance of $540 million at July 24, 2008 to $119.5 million as Dec. 26, 2009, and further reduced to $97 million as of today.

In January 2010, Hologic received $70 million from KV Pharmaceutical Company in connection with an amendment of the original asset purchase agreement relating to the sale of our Gestiva assets.

For more information: www.hologic.com

Related Content

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
Ikonopedia Introduces Automated Combined Reporting Package at SBI
News | Mammography Reporting Software | April 04, 2019
Ikonopedia will introduce its new Automated Combined Reporting package at the 2019 Society of Breast Imaging/American...
Konica Minolta Highlights New Exa Mammo Features at SBI/ACR Breast Imaging Symposium
News | Breast Imaging | April 03, 2019
Konica Minolta Healthcare Americas Inc. will highlight new features of Exa Mammo, a picture archiving and communication...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Lunit Showcases AI Solution for Breast Cancer at SBI 2019
News | Artificial Intelligence | April 02, 2019
Medical artificial intelligence (AI) startup Lunit announced its attendance at the Society of Breast Imaging (SBI) 2019...
Samantha Zuckerman, M.D.

Sizes of words in this “word cloud” correlate to how often each word was used in survey responses to the question: “What do you perceive are the advantages to using synthetic mammography in screening?” In reference to decreased radiation dose to patients, the words “radiation,” “less” and “dose” were most frequently cited. Illustration courtesy of Samantha Zuckerman, M.D.

Feature | Mammography | April 02, 2019 | By Greg Freiherr
Many mammography practices that use digital breast tomosynthesis (DBT) continue to use dosed digital mammography to s